Prime Medicine, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Prime Medicine, Inc. (PRME) reported Adjustments to Additional Paid in Capital, Warrant Issued of $18.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-03
- Prime Medicine, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-03-31 was $18.80M.
- Prime Medicine, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $18.80M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2024-12-31 | $18.80M 10-K · filed 2026-03-03 | |
| 2024-03-31 | $18.80M 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |